These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 30399000)

  • 1. Estimating the Effect of Treatment Duration Using Observational Data in Practice.
    van Geloven N; Dekkers OM; le Cessie S
    Epidemiology; 2019 Mar; 30(2):e7-e8. PubMed ID: 30399000
    [No Abstract]   [Full Text] [Related]  

  • 2. Estimating mean response as a function of treatment duration in an observational study, where duration may be informatively censored.
    Johnson BA; Tsiatis AA
    Biometrics; 2004 Jun; 60(2):315-23. PubMed ID: 15180656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statistical power in parallel group point exposure studies with time-to-event outcomes: an empirical comparison of the performance of randomized controlled trials and the inverse probability of treatment weighting (IPTW) approach.
    Austin PC; Schuster T; Platt RW
    BMC Med Res Methodol; 2015 Oct; 15():87. PubMed ID: 26472109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence-based medicine, systematic reviews, and guidelines in interventional pain management: part 6. Systematic reviews and meta-analyses of observational studies.
    Manchikanti L; Datta S; Smith HS; Hirsch JA
    Pain Physician; 2009; 12(5):819-50. PubMed ID: 19787009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing outcomes on peritoneal and hemodialysis: a case study in the interpretation of observational studies.
    Davies SJ
    Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):24-30. PubMed ID: 17237887
    [No Abstract]   [Full Text] [Related]  

  • 6. Doubly robust estimators of causal exposure effects with missing data in the outcome, exposure or a confounder.
    Williamson EJ; Forbes A; Wolfe R
    Stat Med; 2012 Dec; 31(30):4382-400. PubMed ID: 23086504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is it time to use observational data to estimate treatment effectiveness in multiple sclerosis?
    Trojano M
    Neurology; 2007 Oct; 69(15):1478-9. PubMed ID: 17923610
    [No Abstract]   [Full Text] [Related]  

  • 8. Dynamic treatment regimes.
    Moodie E
    Clin Trials; 2004; 1(5):471. PubMed ID: 16279286
    [No Abstract]   [Full Text] [Related]  

  • 9. Evidence-based reviews and meta-analysis.
    Evans J
    Am J Ophthalmol; 2010 May; 149(5):701-3. PubMed ID: 20399923
    [No Abstract]   [Full Text] [Related]  

  • 10. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations.
    Hannan EL
    JACC Cardiovasc Interv; 2008 Jun; 1(3):211-7. PubMed ID: 19463302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical and statistical issues in missing data for longitudinal patient-reported outcomes.
    Bell ML; Fairclough DL
    Stat Methods Med Res; 2014 Oct; 23(5):440-59. PubMed ID: 23427225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence-based medicine, systematic reviews, and guidelines in interventional pain management: Part 2: Randomized controlled trials.
    Manchikanti L; Hirsch JA; Smith HS
    Pain Physician; 2008; 11(6):717-73. PubMed ID: 19057624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Primary Outcome Is Positive - Is That Good Enough?
    Pocock SJ; Stone GW
    N Engl J Med; 2016 Sep; 375(10):971-9. PubMed ID: 27602669
    [No Abstract]   [Full Text] [Related]  

  • 14. Many multicenter trials had few events per center, requiring analysis via random-effects models or GEEs.
    Kahan BC; Harhay MO
    J Clin Epidemiol; 2015 Dec; 68(12):1504-11. PubMed ID: 25985892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using inverse-weighting in cost-effectiveness analysis with censored data.
    Willan AR; Lin DY; Cook RJ; Chen EB
    Stat Methods Med Res; 2002 Dec; 11(6):539-51. PubMed ID: 12516988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Better reporting and greater homogeneity in outcome measures are seen in randomized trial protocols when guidelines exist.
    Sautenet B; Caille A; Halimi JM; Goupille P; Giraudeau B
    J Clin Epidemiol; 2013 Aug; 66(8):838-46. PubMed ID: 23810024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Observational studies in the era of randomized trials: finding the balance.
    Castillo RC; Scharfstein DO; MacKenzie EJ
    J Bone Joint Surg Am; 2012 Jul; 94 Suppl 1():112-7. PubMed ID: 22810460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generalized estimating equations in cluster randomized trials with a small number of clusters: Review of practice and simulation study.
    Huang S; Fiero MH; Bell ML
    Clin Trials; 2016 Aug; 13(4):445-9. PubMed ID: 27094487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limitations of randomized clinical trials in chronic diseases: explanations and recommendations.
    Pincus T
    Adv Mind Body Med; 2002; 18(2):14-21. PubMed ID: 12629874
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.